Inactive Instrument

MYOS Corp Stock OTC Bulletin Board

Stocks

US5540511020

End-of-day quote OTC Bulletin Board
- USD - Intraday chart for MYOS Corp

Valuation: MYOS Corp

Market Cap 7.25M 6.33M 5.84M 5.39M 10.15M 698M 10.38M 69.85M 27.47M 342M 27.21M 26.62M 1.18B P/E 2021
-1.04x
P/E 2022 -0.41x
Enterprise Value 2.88M 2.51M 2.32M 2.14M 4.03M 277M 4.12M 27.73M 10.91M 136M 10.81M 10.57M 467M EV / Sales 2021
1.74x
EV / Sales 2022 0.46x
Free-Float
-
Yield 2021 *
-
Yield 2022 -

Financials

2021 2022
Net sales 22.13M 19.34M 17.85M 16.45M 31M 2.13B 31.69M 213M 83.89M 1.04B 83.11M 81.28M 3.59B 43.11M 37.67M 34.76M 32.04M 60.4M 4.15B 61.74M 416M 163M 2.03B 162M 158M 7B
Net income -43.82M -38.29M -35.33M -32.57M -61.38M -4.22B -62.75M -422M -166M -2.07B -165M -161M -7.11B -47.62M -41.61M -38.4M -35.39M -66.71M -4.59B -68.19M -459M -181M -2.25B -179M -175M -7.73B
Net Debt -7.44M -6.5M -6M -5.53M -10.43M -717M -10.66M -71.73M -28.21M -351M -27.95M -27.34M -1.21B -4.37M -3.82M -3.52M -3.25M -6.12M -421M -6.26M -42.11M -16.56M -206M -16.41M -16.05M -709M
Logo MYOS Corp
MYOS RENS Technology Inc. is focused on the discovery, development and commercialization of nutritional ingredients, functional foods, and other technologies for maintaining or improving the health and performance of muscle tissue. Its research is focused on developing strategies and therapeutic interventions to address muscle-related conditions, including sarcopenia, cachexia, and inherited and acquired muscle diseases. The Company, through its subsidiary, holds the intellectual property pertaining to Fortetropin, which is a dietary supplement that has been shown in clinical studies to temporarily decrease the levels of serum myostatin, MYO-T12, a formulation containing Fortetropin. Fortetropin is the Company's all-natural food ingredient clinically shown to enhance muscle size, lean body mass and strength as part of resistance training in humans. Fortetropin is made from fertilized chicken egg yolks using a process that retains the biological integrity and bioactivity of the product.
Employees
-
Sector
-